Alvaro Proaño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alvaro Proaño has a total of 126 co-authors. Here are the top co-authors by number of shared publications:
- Eloy Francisco Ruiz
Geriatric Evidence & Research Initiative (GERI‐AMAUTA), Section of Geriatric Medicine, Department of Medicine Rutgers New Jersey Medical School Newark New Jersey USA
7 shared publications - Jorge Coronel
Laboratorio de Investigacion y Desarrollo, Universidad Peruana Cayetano Heredia, San Martin de Porres, Lima, Peru
4 shared publications Luz Caviedes
4 shared publicationsAntonio Salas
3 shared publications- Carlton Aw Evans
IFHAD: Innovation For Health And Development
3 shared publications - Daniela E. Kirwan
Infectious Diseases and Immunity and Wellcome Trust Imperial College Centre for Global Health Research, Imperial College London, United Kingdom
3 shared publications
Latest Publications
- 20 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 748-753
Anti-cytomegalovirus medications among very low birth weight infants in the United States from 2016 to 2023
Very low birth weight (VLBW) infants are at risk for congenital and postnatally acquired cytomegalovirus (CMV). NICU utilization rates for anti-CMV active medications are unknown. We assessed utilization of these medications among VLBW infants admitted to NICUs across the U.S. over an 8-year period. Repeated cross-sectional study using data from the Premier Healthcare Database, including inborn VLBW infants admitted to NICUs from 2016 to 2023. Daily pharmacy charge data were used to estimate the annual proportion of infants who received anti-CMV medications at least once. Among 75,731 VLBW infants admitted to 498 NICUs, 309 (0.4%) infants from 115 NICUs received anti-CMV medications; 228 infants received valganciclovir, 212 infants received ganciclovir. The proportion of VLBW infants receiving these medications was less than 1% annually. Most administrations started after 4 weeks (n = 261,84.5%). Usage of anti-CMV medications among VLBW infants in U.S. NICUs was low and usually administered after 4 weeks.
- 20 April 2026
- Published by Springer Nature in Journal of Perinatology
- Vol. 46 (5) , 748-753
Anti-cytomegalovirus medications among very low birth weight infants in the United States from 2016 to 2023
Very low birth weight (VLBW) infants are at risk for congenital and postnatally acquired cytomegalovirus (CMV). NICU utilization rates for anti-CMV active medications are unknown. We assessed utilization of these medications among VLBW infants admitted to NICUs across the U.S. over an 8-year period. Repeated cross-sectional study using data from the Premier Healthcare Database, including inborn VLBW infants admitted to NICUs from 2016 to 2023. Daily pharmacy charge data were used to estimate the annual proportion of infants who received anti-CMV medications at least once. Among 75,731 VLBW infants admitted to 498 NICUs, 309 (0.4%) infants from 115 NICUs received anti-CMV medications; 228 infants received valganciclovir, 212 infants received ganciclovir. The proportion of VLBW infants receiving these medications was less than 1% annually. Most administrations started after 4 weeks (n = 261,84.5%). Usage of anti-CMV medications among VLBW infants in U.S. NICUs was low and usually administered after 4 weeks.
- 24 August 2025
- Published by Elsevier in Journal of Virological Methods
- Vol. 339, 115245
Detection and characterization of neonatal cytomegalovirus through nanopore sequencing using flongle flow cells: Pilot study in Philadelphia, Pennsylvania
- 24 August 2025
- Published by Elsevier in Journal of Virological Methods
- Vol. 339, 115245
Detection and characterization of neonatal cytomegalovirus through nanopore sequencing using flongle flow cells: Pilot study in Philadelphia, Pennsylvania
- 22 August 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (11) , 2449-2450
EBNEO Commentary: Respiratory syncytial virus vaccine in pregnancy for infant protection
- 22 August 2023
- Published by Wiley in Acta Paediatrica
- Vol. 112 (11) , 2449-2450
EBNEO Commentary: Respiratory syncytial virus vaccine in pregnancy for infant protection
- Open Access
- 24 June 2023
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 52 (6) , 1870-1877
Effect of preterm birth on growth and blood pressure in adulthood in the Pelotas 1993 cohort
Background: Preterm birth has been associated with increased risk of hypertension and cardiovascular disease later in adulthood, attributed to cardiovascular and metabolic alterations in early life. However, there is paucity of evidence from low- and middle-income countries (LMICs). Methods: We investigated the differences between preterm (<37 weeks gestational age) and term-born individuals in birth length and weight as well as adult (18 and 20 years) height, weight and blood pressure in the Brazilian 1993 Pelotas birth cohort using linear regressions. Analyses were adjusted for the maternal weight at the beginning of pregnancy and maternal education and family income at childbirth. Additional models were adjusted for body mass index (BMI) and birthweight. Separate analyses were run for males and females. The complete sample was analysed with an interaction term for sex. Results: Of the 3585 babies included at birth, 3010 were followed up in adulthood at 22 years. Preterm participants had lower length and weight at birth. This difference remained for male participants in adulthood, but female participants were no shorter than their term counterparts by 18 years of age. At 22 years, females born preterm had lower blood pressures (systolic blood pressure −1.00 mmHg, 95%CI −2.7, 0.7 mmHg; diastolic blood pressure −1.1 mmHg, 95%CI −2.4, 0.3 mmHg) than females born at term. These differences were not found in male participants. Conclusions: In this Brazilian cohort we found contrasting results regarding the association of preterm birth with blood pressure in young adulthood, which may be unique to an LMIC.
- 24 June 2023
- Published by Oxford University Press (OUP) in International Journal of Epidemiology
- Vol. 52 (6) , 1870-1877
Open AccessEffect of preterm birth on growth and blood pressure in adulthood in the Pelotas 1993 cohort
Background: Preterm birth has been associated with increased risk of hypertension and cardiovascular disease later in adulthood, attributed to cardiovascular and metabolic alterations in early life. However, there is paucity of evidence from low- and middle-income countries (LMICs). Methods: We investigated the differences between preterm (<37 weeks gestational age) and term-born individuals in birth length and weight as well as adult (18 and 20 years) height, weight and blood pressure in the Brazilian 1993 Pelotas birth cohort using linear regressions. Analyses were adjusted for the maternal weight at the beginning of pregnancy and maternal education and family income at childbirth. Additional models were adjusted for body mass index (BMI) and birthweight. Separate analyses were run for males and females. The complete sample was analysed with an interaction term for sex. Results: Of the 3585 babies included at birth, 3010 were followed up in adulthood at 22 years. Preterm participants had lower length and weight at birth. This difference remained for male participants in adulthood, but female participants were no shorter than their term counterparts by 18 years of age. At 22 years, females born preterm had lower blood pressures (systolic blood pressure −1.00 mmHg, 95%CI −2.7, 0.7 mmHg; diastolic blood pressure −1.1 mmHg, 95%CI −2.4, 0.3 mmHg) than females born at term. These differences were not found in male participants. Conclusions: In this Brazilian cohort we found contrasting results regarding the association of preterm birth with blood pressure in young adulthood, which may be unique to an LMIC.
- Open Access
- 15 May 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (5) , 277
Chagas Disease Diagnostic Testing in Two Academic Hospitals in New Orleans, Louisiana: A Call to Action
Chagas disease, caused by the protozoa parasite Trypanosoma cruzi, is an anthropozoonosis that represents a major public health problem in the Americas, affecting 7 million people with at least 65 million at risk. We sought to assess the intensity of disease surveillance based on diagnostic test requests from hospitals in New Orleans, Louisiana. We extracted information from send-out labs at two major tertiary academic hospitals in New Orleans, Louisiana, USA, from 1 January 2018 to 1 December 2020. We found that in these three years there were 27 patients for whom Chagas disease testing was ordered. Most of these patients were male (70%), with a median age of 40 years old, and their most common ethnical background was Hispanic (74%). These findings demonstrate undertesting of this neglected disease in our region. Given the low Chagas disease surveillance, we need to increase awareness, health promotion, and education among healthcare workers.
- 15 May 2023
- Published by MDPI AG in Tropical Medicine and Infectious Disease
- Vol. 8 (5) , 277
Open AccessChagas Disease Diagnostic Testing in Two Academic Hospitals in New Orleans, Louisiana: A Call to Action
Chagas disease, caused by the protozoa parasite Trypanosoma cruzi, is an anthropozoonosis that represents a major public health problem in the Americas, affecting 7 million people with at least 65 million at risk. We sought to assess the intensity of disease surveillance based on diagnostic test requests from hospitals in New Orleans, Louisiana. We extracted information from send-out labs at two major tertiary academic hospitals in New Orleans, Louisiana, USA, from 1 January 2018 to 1 December 2020. We found that in these three years there were 27 patients for whom Chagas disease testing was ordered. Most of these patients were male (70%), with a median age of 40 years old, and their most common ethnical background was Hispanic (74%). These findings demonstrate undertesting of this neglected disease in our region. Given the low Chagas disease surveillance, we need to increase awareness, health promotion, and education among healthcare workers.
- Open Access
- 6 June 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (11) , 1546-1549
Addressing bias and knowledge gaps regarding race and ethnicity in neonatology manuscript review
A recent shift in public attention to racism, racial disparities, and health equity have resulted in an abundance of calls for relevant papers and publications in academic journals. Peer-review for such articles may be susceptible to bias, as subject matter expertise in the evaluation of social constructs, like race, is variable. From the perspective of researchers focused on neonatal health equity, we share our positive and negative experiences in peer-review, provide relevant publicly available data regarding addressing bias in peer-review from 12 neonatology-focused journals, and give recommendations to address bias and knowledge gaps in the peer review process of health equity research.
- 6 June 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (11) , 1546-1549
Open AccessAddressing bias and knowledge gaps regarding race and ethnicity in neonatology manuscript review
A recent shift in public attention to racism, racial disparities, and health equity have resulted in an abundance of calls for relevant papers and publications in academic journals. Peer-review for such articles may be susceptible to bias, as subject matter expertise in the evaluation of social constructs, like race, is variable. From the perspective of researchers focused on neonatal health equity, we share our positive and negative experiences in peer-review, provide relevant publicly available data regarding addressing bias in peer-review from 12 neonatology-focused journals, and give recommendations to address bias and knowledge gaps in the peer review process of health equity research.
- 31 March 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (10) , 1409-1411
#neoTwitter: evaluation of its use within the neonatal-perinatal community
- 31 March 2022
- Published by Springer Nature in Journal of Perinatology
- Vol. 42 (10) , 1409-1411
#neoTwitter: evaluation of its use within the neonatal-perinatal community
- Open Access
- 1 April 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 105, 357-373
Risk factors for vertical transmission of Chagas disease: A systematic review and meta-analysis
- 1 April 2021
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 105, 357-373
Open AccessRisk factors for vertical transmission of Chagas disease: A systematic review and meta-analysis
- 28 September 2020
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 60 (1) , 75-78
Posttransplant Lymphoproliferative Disorder Presenting as Ptosis, Fever, and Regression of Milestones 7 Months After Liver Transplant
- 28 September 2020
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 60 (1) , 75-78
Posttransplant Lymphoproliferative Disorder Presenting as Ptosis, Fever, and Regression of Milestones 7 Months After Liver Transplant
- Open Access
- 17 April 2019
- Published by Springer Nature in Critical Care
- Vol. 23 (1) , 130
Sedation practices and clinical outcomes in mechanically ventilated patients in a prospective multicenter cohort
We sought to study the association between sedation status, medications (benzodiazepines, opioids, and antipsychotics), and clinical outcomes in a resource-limited setting. A longitudinal study of critically ill participants on mechanical ventilation. Five intensive care units (ICUs) in four public hospitals in Lima, Peru. One thousand six hundred fifty-seven critically ill participants were assessed daily for sedation status during 28 days and vital status by day 90. After excluding data of participants without a Richmond Agitation Sedation Scale score and without sedation, we followed 1338 (81%) participants longitudinally for 18,645 ICU days. Deep sedation was present in 98% of participants at some point of the study and in 12,942 ICU days. Deep sedation was associated with higher mortality (interquartile odds ratio (OR) = 5.42, 4.23–6.95; p < 0.001) and a significant decrease in ventilator (− 7.27; p < 0.001), ICU (− 4.38; p < 0.001), and hospital (− 7.00; p < 0.001) free days. Agitation was also associated with higher mortality (OR = 39.9, 6.53–243, p < 0.001). The most commonly used sedatives were opioids and benzodiazepines (9259 and 8453 patient days respectively), and the latter were associated with a 41% higher mortality in participants with a higher cumulative dose (75th vs 25th percentile, interquartile OR = 1.41, 1.12–1.77; p < 0.01). The overall cumulative dose of benzodiazepines and opioids was high, 774.5 mg and 16.8 g, respectively, by day 7 and by day 28; these doses approximately doubled. Haloperidol was only used in 3% of ICU days; however, the use of it was associated with a 70% lower mortality (interquartile OR = 0.3, 0.22–0.44, p < 0.001). Deep sedation, agitation, and cumulative dose of benzodiazepines were all independently associated with higher 90-day mortality. Additionally, deep sedation was associated with less ventilator-, ICU-, and hospital-free days. In contrast, haloperidol was associated with lower mortality in our study.
- 17 April 2019
- Published by Springer Nature in Critical Care
- Vol. 23 (1) , 130
Open AccessSedation practices and clinical outcomes in mechanically ventilated patients in a prospective multicenter cohort
We sought to study the association between sedation status, medications (benzodiazepines, opioids, and antipsychotics), and clinical outcomes in a resource-limited setting. A longitudinal study of critically ill participants on mechanical ventilation. Five intensive care units (ICUs) in four public hospitals in Lima, Peru. One thousand six hundred fifty-seven critically ill participants were assessed daily for sedation status during 28 days and vital status by day 90. After excluding data of participants without a Richmond Agitation Sedation Scale score and without sedation, we followed 1338 (81%) participants longitudinally for 18,645 ICU days. Deep sedation was present in 98% of participants at some point of the study and in 12,942 ICU days. Deep sedation was associated with higher mortality (interquartile odds ratio (OR) = 5.42, 4.23–6.95; p < 0.001) and a significant decrease in ventilator (− 7.27; p < 0.001), ICU (− 4.38; p < 0.001), and hospital (− 7.00; p < 0.001) free days. Agitation was also associated with higher mortality (OR = 39.9, 6.53–243, p < 0.001). The most commonly used sedatives were opioids and benzodiazepines (9259 and 8453 patient days respectively), and the latter were associated with a 41% higher mortality in participants with a higher cumulative dose (75th vs 25th percentile, interquartile OR = 1.41, 1.12–1.77; p < 0.01). The overall cumulative dose of benzodiazepines and opioids was high, 774.5 mg and 16.8 g, respectively, by day 7 and by day 28; these doses approximately doubled. Haloperidol was only used in 3% of ICU days; however, the use of it was associated with a 70% lower mortality (interquartile OR = 0.3, 0.22–0.44, p < 0.001). Deep sedation, agitation, and cumulative dose of benzodiazepines were all independently associated with higher 90-day mortality. Additionally, deep sedation was associated with less ventilator-, ICU-, and hospital-free days. In contrast, haloperidol was associated with lower mortality in our study.